CL2023003301A1 - Métodos de dosificación y tratamiento con una proteína inmunomoduladora de fusión taci-fc - Google Patents

Métodos de dosificación y tratamiento con una proteína inmunomoduladora de fusión taci-fc

Info

Publication number
CL2023003301A1
CL2023003301A1 CL2023003301A CL2023003301A CL2023003301A1 CL 2023003301 A1 CL2023003301 A1 CL 2023003301A1 CL 2023003301 A CL2023003301 A CL 2023003301A CL 2023003301 A CL2023003301 A CL 2023003301A CL 2023003301 A1 CL2023003301 A1 CL 2023003301A1
Authority
CL
Chile
Prior art keywords
taci
dosage
treatment methods
immunomodulatory protein
baff
Prior art date
Application number
CL2023003301A
Other languages
English (en)
Spanish (es)
Inventor
Dillon Stacey
Yang Jing
L Peng Stanford
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of CL2023003301A1 publication Critical patent/CL2023003301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CL2023003301A 2021-05-07 2023-11-06 Métodos de dosificación y tratamiento con una proteína inmunomoduladora de fusión taci-fc CL2023003301A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163186027P 2021-05-07 2021-05-07
US202163239899P 2021-09-01 2021-09-01
US202163256505P 2021-10-15 2021-10-15
US202163278072P 2021-11-10 2021-11-10
US202263329325P 2022-04-08 2022-04-08

Publications (1)

Publication Number Publication Date
CL2023003301A1 true CL2023003301A1 (es) 2024-06-21

Family

ID=81851023

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003301A CL2023003301A1 (es) 2021-05-07 2023-11-06 Métodos de dosificación y tratamiento con una proteína inmunomoduladora de fusión taci-fc

Country Status (13)

Country Link
US (1) US20240279310A1 (cg-RX-API-DMAC10.html)
EP (1) EP4333869A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024518163A (cg-RX-API-DMAC10.html)
KR (1) KR20240019124A (cg-RX-API-DMAC10.html)
CN (3) CN119236057A (cg-RX-API-DMAC10.html)
AU (1) AU2022269139A1 (cg-RX-API-DMAC10.html)
CA (1) CA3216795A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003301A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023016161A2 (cg-RX-API-DMAC10.html)
IL (1) IL308336A (cg-RX-API-DMAC10.html)
MX (1) MX2023013114A (cg-RX-API-DMAC10.html)
PE (1) PE20240641A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022236335A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
US12202882B2 (en) 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
US20260125451A1 (en) * 2022-08-29 2026-05-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fusion protein comprising taci polypeptide and use thereof
IL319997A (en) * 2022-10-04 2025-06-01 Alpine Immune Sciences Inc Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
WO2024114777A1 (zh) * 2022-12-02 2024-06-06 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗微小病变型肾病的方法
WO2024120458A1 (zh) * 2022-12-07 2024-06-13 荣昌生物制药(烟台)股份有限公司 TACI-Fc融合蛋白液体药物制剂
EP4748393A1 (en) * 2023-07-06 2026-05-27 RemeGen Co., Ltd. Method for treating anca-associated vasculitis using taci-fc fusion protein
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法
WO2026067736A1 (zh) * 2024-09-30 2026-04-02 盛禾(中国)生物制药有限公司 一种特异性结合bdca2的抗体及bdca2-taci抗体融合蛋白
WO2026122561A2 (en) 2024-12-03 2026-06-11 Otsuka America Pharmaceutical, Inc. Methods of treating sjögren's disease
WO2026153508A1 (en) * 2025-01-17 2026-07-23 Hansoh Bio Llc Polypeptide and fusion protein and use thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
EP0584266B1 (en) 1991-05-06 2003-09-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Recombinant virus expressing carcinoembryonic antigen and methods of use thereof
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
WO1996009380A1 (en) 1994-09-23 1996-03-28 The University Of British Columbia Method of enhancing expression of mhc class i molecules bearing endogenous peptides
ATE197765T1 (de) 1994-10-03 2000-12-15 Us Gov Health & Human Serv Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
NZ334309A (en) 1996-10-25 2000-08-25 Human Genome Sciences Inc Neutrokine alpha protein, a member of the TNF family, and its use in treating and/or detecting immune disorders
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
CN1348463A (zh) 1998-08-07 2002-05-08 华盛顿大学 免疫学单纯疱疹病毒抗原及其使用方法
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
CZ303272B6 (cs) 1999-01-07 2012-07-11 Zymogenetics, Inc. Farmaceutický prostredek obsahující fúzní protein, izolovaná molekula polynukleotidu, expresní vektor, kultivovaná bunka, zpusob prípravy polypeptidu a izolovaný polypeptid
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
US6596535B1 (en) 1999-08-09 2003-07-22 Targeted Genetics Corporation Metabolically activated recombinant viral vectors and methods for the preparation and use
PL403488A1 (pl) 2001-05-24 2013-07-08 Zymogenetics, Inc. Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
EP3342782B1 (en) 2004-07-15 2022-08-17 Xencor, Inc. Optimized fc variants
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JP4958555B2 (ja) 2004-09-22 2012-06-20 協和発酵キリン株式会社 安定化されたヒトIgG4抗体
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
WO2007134326A2 (en) * 2006-05-15 2007-11-22 Ares Trading S.A. Methods for treating autoimmune diseases using a taci-ig fusion molecule
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
ES2681195T3 (es) * 2007-06-13 2018-09-12 Zymogenetics, Inc Utilización de la proteína de fusión TACI-Ig, tal como atacicept, para la fabricación de un medicamento para el tratamiento de lupus eritematoso
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
LT2222861T (lt) 2007-12-11 2018-03-26 The University Of North Carolina At Chapel Hill Retrovirusiniai vektoriai modifikuoti polipurino atkarpa
AU2012211725A1 (en) * 2011-02-02 2013-08-29 Daiichi Sankyo Company, Limited Peptide library
WO2012125850A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Fc variants
NZ616304A (en) 2011-04-08 2016-01-29 Immune Design Corp Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN104302408B (zh) 2012-02-27 2016-12-14 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
US10562954B2 (en) * 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
MX2017000630A (es) 2014-07-15 2017-04-27 Immune Design Corp Regimenes de sensibilización-refuerzo con un adyuvante de agonista tlr4 y un vector lentiviral.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
US20170145086A1 (en) 2015-11-25 2017-05-25 Visterra, Inc. Antibody molecules to april and uses thereof
US12202882B2 (en) * 2020-05-08 2025-01-21 Alpine Immune Sciences, Inc. APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Also Published As

Publication number Publication date
PE20240641A1 (es) 2024-04-04
AU2022269139A1 (en) 2023-11-16
WO2022236335A1 (en) 2022-11-10
IL308336A (en) 2024-01-01
CN119236057A (zh) 2025-01-03
KR20240019124A (ko) 2024-02-14
CO2023016161A2 (es) 2023-12-11
CN119236055A (zh) 2025-01-03
MX2023013114A (es) 2023-11-17
CN119236056A (zh) 2025-01-03
CA3216795A1 (en) 2022-11-10
EP4333869A1 (en) 2024-03-13
JP2024518163A (ja) 2024-04-25
US20240279310A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
CO2023016161A2 (es) Métodos de dosificación y tratamiento con una proteína inmunomoduladora de fusión taci-fc
CO2022017780A2 (es) Proteínas inmunomoduladoras inhibidoras de april y baff y métodos de uso de las mismas
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
CO2017003070A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
BR112014009851A2 (pt) moduladores de receptor de nmda e usos dos mesmos
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
DOP2024000028A (es) Degradadores bifuncionales de quinasas asociadas al receptor de interleucina 1 y usos terapéuticos de los mismos
BR112015018094A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112022012033A2 (pt) Antagonistas do receptor de melanocortina subtipo-2 (mc2r) de piperidina gem-dissubstituída e seus usos
BR112014031730A2 (pt) entidades químicas, composições farmacêuticas, compostos ou sais farmaceuticamente aceitáveis dos mesmos, usos de entidades químicas ou composições e métodos para tratar doenças, distúrbios ou condições médicas mediadas pela atividade enzimática de pde1 e para modular a atividade da enzima pde1
MX2025003628A (es) Métodos y usos de la proteína de fusión taci-fc inmunomoduladora
BR112015018087A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
AR099101A1 (es) Dispositivo de fijación externo para tratar fracturas óseas
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
BR112012032282A2 (pt) administração transdérmica de memantina
MX386334B (es) Cèlulas t y sus usos en el tratamiento de trastornos linfoproliferativos asociados al virus de epstein-barr.
PH12022551035A1 (en) Siglec-9 ecd fusion molecules and methods of use thereof
MX2021015506A (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b.
MX2024010165A (es) Metodos para tratar la miositis mediante el uso de antagonistas de fcrn.
BR112017012588B8 (pt) Compostos heteroaril-heteroarila bicíclicos de ácido benzoico, seus usos, composições farmacêuticas, métodos de preparação destas e métodos para provocar ou promover o desenvolvimento de neuritos, o crescimento de neuritos e/ou a regeneração de neuritos e para ativar o receptor beta do ácido retinoico
CO6290694A2 (es) Paramyxovirus eficaz como antitumoral
UA112970C2 (uk) Інактивований вірус вітряної віспи, спосіб його одержання і застосування
MX2022004212A (es) Moduladores de atf6 y usos de los mismos.